Rituximab-Induced Alopecia Universalis in a Patient With Bullous Pemphigoid

August 2022 | Volume 21 | Issue 8 | 894 | Copyright © August 2022


Published online August 1, 2022

Tudor Puiu MDa, Danielle Reimer MDa, Olayemi Sokumbi MDa,b

aDepartment of Dermatology, Mayo Clinic Florida, Jacksonville, FL
bDepartment of Laboratory Medicine & Pathology, Mayo Clinic Florida, Jacksonville, FL

Abstract
Alopecia areata is a CD8+ T-lymphocyte driven autoimmune disorder leading to reversible hair loss. While most commonly presenting as isolated well-demarcated non-cicatricial alopecic patches on the scalp, subtypes of alopecia areata include alopecia totalis with loss of all scalp hair and alopecia universalis with complete loss of all body hair. Although primarily an idiopathic condition, several triggers, including medications, have been reported in the literature. To the best of our knowledge, we present the first reported case of rituximab, a chimeric anti-CD20 receptor monoclonal antibody, inducing alopecia universalis on two separate occasions during the treatment of bullous pemphigoid in a 55-year-old female. While the exact mechanism driving this association remains unclear, greater insights into the pathophysiology of alopecia areata/universalis may help to further explain this association and provide greater insight into other possible therapeutic options.

J Drugs Dermatol. 2022;21(8):894-895. doi:10.36849/JDD.6690

CASE PRESENTATION

A 55-year-old female with a history of hypertension and discoid lupus presented to dermatology clinic with widespread urticated tense bullae and crusted erosions present for several months (Figure 1), consistent with bullous pemphigoid on further tissue and serological evaluation. Treatment was initiated with a prolonged prednisone taper, starting at 1 mg/kg, in conjunction with mycophenolate mofetil at a dose of 1 g daily. Although well-controlled initially, breakthrough blistering was noted approximately 6 months into the treatment course. At that time, the risks and benefits of the off-label use of rituximab for bullous pemphigoid was discussed,1-2 and patient elected to proceed with rituximab treatment.

The patient presented in follow up one month after completing two loading doses of rituximab 1,000 mg IV spaced two weeks apart with subsequent complete resolution of blistering and pruritus. Over the next few months, she developed progressive and eventually complete non-scarring alopecia involving the scalp, eyebrows, and eyelashes. Of note, our patient did have a background of previous scattered atrophic cicatricial alopecic plaques involving the scalp in areas of discoid lupus involvement (Figure 2). Biopsy obtained from an area of scarring on the scalp demonstrated features consistent with her known